Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
This report contains market size and forecasts of Non-Insulin Therapies for Diabetes in China, including the following market information:
China Non-Insulin Therapies for Diabetes Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Non-Insulin Therapies for Diabetes companies in 2020 (%)
The global Non-Insulin Therapies for Diabetes market size is expected to growth from US$ 31940 million in 2020 to US$ 59820 million by 2027; it is expected to grow at a CAGR of 8.9% during 2021-2027.
The China Non-Insulin Therapies for Diabetes market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Non-Insulin Therapies for Diabetes Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Non-Insulin Therapies for Diabetes Market,
China Non-Insulin Therapies for Diabetes Market Segment Percentages,
Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
China Non-Insulin Therapies for Diabetes Market,
China Non-Insulin Therapies for Diabetes Market Segment Percentages,
Monitoring
Diagnosis
Treatment
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Insulin Therapies for Diabetes revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Non-Insulin Therapies for Diabetes revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
China Non-Insulin Therapies for Diabetes Market Revenue, 2016-2021, 2022-2027, ($ millions)
China top five Non-Insulin Therapies for Diabetes companies in 2020 (%)
The global Non-Insulin Therapies for Diabetes market size is expected to growth from US$ 31940 million in 2020 to US$ 59820 million by 2027; it is expected to grow at a CAGR of 8.9% during 2021-2027.
The China Non-Insulin Therapies for Diabetes market was valued at US$ XX million in 2020 and is projected to reach US$ XX million by 2027, at a CAGR of XX% during the forecast period.
QYResearch has surveyed the Non-Insulin Therapies for Diabetes Companies and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
China Non-Insulin Therapies for Diabetes Market,
By Type
, 2016-2021, 2022-2027 ($ Millions)China Non-Insulin Therapies for Diabetes Market Segment Percentages,
By Type
, 2020 (%)Alpha-glucosidase Inhibitors
Amylin Agonists
Biguanides
Dipeptidyl Peptidase-4 (DPP4) Inhibitors
Glinides / Meglitinides
GLP-1 Analogs / GLP-1 Agonists
Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
Sulfonylureas
Thiazolidinediones
Others
China Non-Insulin Therapies for Diabetes Market,
By Application
, 2016-2021, 2022-2027 ($ Millions)China Non-Insulin Therapies for Diabetes Market Segment Percentages,
By Application
, 2020 (%)Monitoring
Diagnosis
Treatment
Others
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Insulin Therapies for Diabetes revenues in China market, 2016-2021 (Estimated), ($ millions)
Key companies Non-Insulin Therapies for Diabetes revenues share in China market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Pfizer
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Jiangsu Hengrui Medicine
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
